Cellebrite DI Ltd. $CLBT Stake Trimmed by Greenhaven Road Investment Management L.P.

Greenhaven Road Investment Management L.P. lowered its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 3.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,599,937 shares of the company’s stock after selling 53,110 shares during the quarter. Cellebrite DI makes up approximately 4.8% of Greenhaven Road Investment Management L.P.’s investment portfolio, making the stock its 4th largest holding. Greenhaven Road Investment Management L.P.’s holdings in Cellebrite DI were worth $28,847,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of CLBT. Advisory Services Network LLC bought a new stake in shares of Cellebrite DI in the third quarter valued at approximately $40,000. CWM LLC raised its position in shares of Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the period. First Horizon Corp raised its position in shares of Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after purchasing an additional 2,337 shares during the period. Vestcor Inc bought a new stake in shares of Cellebrite DI in the third quarter valued at approximately $70,000. Finally, PNC Financial Services Group Inc. raised its position in shares of Cellebrite DI by 114.5% in the third quarter. PNC Financial Services Group Inc. now owns 4,501 shares of the company’s stock valued at $83,000 after purchasing an additional 2,403 shares during the period. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of NASDAQ:CLBT opened at $12.84 on Friday. The company has a 50 day moving average of $13.23 and a 200 day moving average of $15.05. The stock has a market cap of $3.20 billion, a P/E ratio of 45.86, a P/E/G ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98.

Insider Buying and Selling

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. The trade was a 2.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 13,269 shares of company stock valued at $169,592. 5.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CLBT shares. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, DA Davidson began coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.